The TRIPS Agreement enforces global patent rules that block access to affordable generic medicines, especially in low-income countries. Despite flexibilities like compulsory licensing, complex rules, trade threats, and corporate lobbying have made them nearly impossible to use - leaving billions without life-saving drugs.